Upregulation of PARP1 is observed in cancers with BRCA gene defects and has been shown to enhance the resistance of cancers to DNA‐damaging therapies, hence making its inhibition an attractive field of study in pharmaceutical research [31]. This evidence concerns the gene PARP1 and cancer.